(A61K39/395)

ethod for recombinant polypeptide production // 2628310
FIELD: pharmacology.SUBSTANCE: method for antibody production, a method for production of a pharmaceutical preparation containing an antibody obtained by this method, a nucleic acid molecule, application of a vector containing such nucleic acid molecule, and application of a cell where the said nucleic acid molecule or vector is artificially introduced in the method for antibody production. This method for antibody production involves culturing a cell that expresses an antibody-enhancing sequence (APES) that has been artificially inserted into a cell and into which an exogenous DNA encoding the desired antibody was introduced to produce the desired antibody, and wherein APES is a nucleic acid molecule containing a nucleotide sequence that can bind to DNA or mRNA of NfkBia gene derived from a human, mouse, rat, or hamster by base pairing, and can suppress expression of the NfkBia gene.EFFECT: invention allows production of an antibody at a high level with suppression of NfkBia expression.16 cl, 29 dwg, 8 ex

Rsv-specific binding molecules and means for their obtaining // 2628095
FIELD: biotechnology.SUBSTANCE: isolated antibody or a functional part thereof, capable of specifically binding the respiratory syncytial virus (RSV), is proposed. A nucleic acid molecule encoding the antibody is also provided. An expression vector and isolated cells comprising the said nucleic acid molecule for production of said antibody are described. In addition, the invention relates to a method for production of the said antibody, as well as to application of the said antibody in methods for RSV-related disorder treatment or prevention.EFFECT: invention allows to effectively bind RSV and can be used for RSV-related disorders therapy.27 cl, 16 dwg, 2 tbl, 5 ex

Antibodies, capable of specific connecting with her2 // 2628094
FIELD: biotechnology.SUBSTANCE: human epidermal growth factor 2 (HER2) receptor antibody is proposed, as well as pharmaceutical compositions comprising the said antibody for malignant tumour prevention and treatment and for apoptosis induction. In addition, a kit for malignant tumour diagnosing, comprising the said antibody, is provided.EFFECT: invention allows cancer cells destruction with significantly increased cytotoxicity when used in combination with trastuzumab and can be used for cancer therapy.11 cl, 27 dwg, 10 tbl, 15 ex

New binding molecules with anti-tumour activity // 2627185
FIELD: biotechnology.SUBSTANCE: binding molecule specifically binding to two different epitopes on HER2 and a method for its preparation, as well as a nucleic acid encoding it, expressing a vector comprising this nucleic acid molecule, a host cell for expression of a binding molecule transformed with the expression vector, and a pharmaceutical composition for cancer treatment comprising a binding molecule or a nucleic acid molecule encoding it, or an expression vector, are proposed. The proposed binding molecule comprises the first polypeptide comprising an amino acid sequence that is at least 90% identical to SEQ ID NO:1, and the second heavy and light chain antibody polypeptide comprising amino acid sequences at least 95% identical to SEQ ID NO:NO:154 and SEQ ID NO:155, respectively. The presented group of inventions is applicable in medicine for anti-tumour therapy.EFFECT: binding molecule effectively suppresses the tumour cells growth and shows high antiproliferative activity.17 cl, 13 dwg, 1 tbl, 14 ex

New modulators and methods of their application // 2627176
FIELD: biotechnology.SUBSTANCE: antibody specifically binding to PTK7 (human protein tyrosine kinase 7), as well as a conjugate of the said antibody with a cytotoxic agent, is claimed. Nucleic acids encoding the antibody are also provided and include expression vectors and host cells. In addition, methods for application of the said antibody, including conjugate, for cancer diagnosis and treatment are provided.EFFECT: effective targeting of tumour stem cells, which can be used to treat patients suffering from a wide range of malignant tumours.52 cl, 42 dwg, 5 tbl, 16 ex

Il-1 alpha and beta bispecific immunoglobulins with double variable domains and their application // 2627171
FIELD: biotechnology.SUBSTANCE: binding proteins, represented by immunoglobulins with double variable domains that bind IL-1α and IL-1β are claimed. In addition, the invention relates to methods for preparation, as well as application of these proteins, including as part of a pharmaceutical composition, for treatment of a disease or disorder in which the IL-1α and IL-1β or IL-1β activity is malicious.EFFECT: invention allows IL-1α binding with IL-1β with high affinity .32 cl, 2 dwg, 24 tbl, 2 ex

Anti-clusterin antibodies and antigen-binding fragments and their use for tumours volume reduction // 2627163
FIELD: biotechnology.SUBSTANCE: clusterin-binding antibody and an antigen-binding fragment thereof are proposed. Nucleic acids encoding variable regions of antibodies, an expression vector; a cell; a kit and a method for production of an antibody or an antigen-binding fragment thereof are described. Also a pharmaceutical composition for cancer cell growth reduction or tumour cells volume reduction; combination for cancer treatment, and a pharmaceutical composition comprising a chemotherapeutic agent; a method for cancer cell growth reduction or tumour cells volume reduction; a method for carcinomas treatment; kit for application in cancer treatment or detection; use of an antibody or an antigen-binding fragment thereof for tumour volume reduction. The invention may find further application for treatment of diseases associated with clusterin.EFFECT: antibody of the present invention is a humanized form of murine antibody 16B5 and has an approximately equal binding affinity for clusterin.28 cl, 16 dwg, 1 tbl, 6 ex
Production of immunoglobulins with reduced thrombogenic agent content, and immunoglobulin composition // 2627162
FIELD: biotechnology.SUBSTANCE: methods include plasma fractionation according to Cohn, and/or Kistler-Nitschmann to obtain an immunoglobulin-containing solution. Then, the immunoglobulin solution is contacted with a cation exchanger equilibrated at a pH of 3.8 to 5.3, for factor XI, factor XIa, and kallikrein binding, and with an anion exchanger equilibrated at a pH of 7 to 8.2, for prekallikrein binding. Then, the unbound immunoglobulin-containing fractions are collected. The resulting immunoglobulin composition comprises 4-10% of the total protein and is suitable for treating patients with immunodeficiency, inflammatory disease, autoimmune disease, or acute infection.EFFECT: invention maximizes thrombogenic agents factor XI, factor XIa, kallikrein and prekallikrein removal from the immunoglobulin solution using a cation exchanger in a very narrow range of pH values, while maintaining a constant level of immunoglobulin in the solution.49 cl, 16 tbl, 14 ex
Concentrated protein pharmaceutical compositions and their application // 2626512
FIELD: pharmacology.SUBSTANCE: group of inventions concerns low-viscosity hypotonic pharmaceutical compositions containing a concentrated PRO 140 monoclonal antibody in an amount of 100 to 200 mg/ml, a tonicity regulator in the form of a salt selected from sodium chloride, sodium gluconate or sodium lactate in an amount of 90 to 95 mM, and a buffer solution. They are used in pharmaceutical compositions and finished products.EFFECT: possibility of subcutaneous administration or delivery of a high concentration of a protein drug, such as PRO 140 monoclonal antibody, to a subject suffering from a disease or condition that can be cured with the said protein drug.81 cl, 7 ex, 1 tbl

Combined therapy with cd19 antibody and nitrogen mustard // 2625222
FIELD: biotechnology.SUBSTANCE: CD19-specific antibody in synergistic combination with bendamustine for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia is declared.EFFECT: invention provides for synergistic antitumor activity of specific CD19 antibodies and of bendamustine that can be used for effective treatment of B-cell malignancies.7 cl, 10 dwg, 10 tbl, 3 ex

Antibodies and other molecules binding b7-h1 and pd-1 // 2625034
FIELD: pharmacology.SUBSTANCE: group of inventions is described comprising an antibody or an antigen-binding fragment thereof that binds to PD-1; a humanized antibody or antigen-binding fragment thereof; a pharmaceutical composition for treatment of a disease associated with B7-H1 interaction with PD-1; a method for malignant tumour treatment in an individual, as well as a method for treatment of an infectious disease associated with the B7-H1 interaction with PD-1, wherein the above methods comprise administration of a pharmaceutical composition; application of the above antibody or antigen-binding fragment for preparation of a drug for malignant tumour treatment, as well as for preparation of a drug for treatment of an infectious disease associated with the B7-H1 interaction with PD-1; method for detection or diagnosis of a disease, disorder or infection associated with B7-H1 interaction with PD-1, method to monitor the disease, disorder or infection progression, method to monitor the response to disease, disorder or infection treatment, method for treatment of a disease associated with an increased PD-1 expression, method for treatment of diseases associated with an increased expression of B7-H1, where the methods include application of the aforementioned antibody or the antigen-binding fragment thereof.EFFECT: invention extends the arsenal of antibodies that bind to PD-1.37 cl, 20 dwg, 23 tbl, 7 ex

Pharmaceutical composition for cancer treatment and prevention // 2624049
FIELD: pharmacology.SUBSTANCE: invention relates to an antibody or a binding fragment thereof, wherein the antibody or a binding fragment thereof specifically binds CAPRIN-1 protein and has immunological reactivity to CAPRIN-1 protein, its encoding DNA, and also to a pharmaceutical composition for treatment or prevention of cancer, expressing CAPRIN-1, and to a conjugate capable of specifically binding CAPRIN-1 protein. A method of treatment or prevention of cancer expressing CAPRIN-1 using the aforementioned antibody or fragment thereof and to a pharmaceutical combination for treatment or prevention of cancer expressing CAPRIN-1, comprising the aforementioned pharmaceutical composition and a pharmaceutical composition comprising an antitumor agent, are described as well.EFFECT: invention enables efficient treatment or prevention of cancer expressing CAPRIN-1.8 cl, 7 ex

Homodimer protein construction // 2624041
FIELD: biotechnology.SUBSTANCE: invention relates to a nucleic acid molecule which encodes an amino acid chain capable of forming a dimeric protein and to the said dimeric protein. The said dimeric protein is used as a vaccine. It contains two identical amino acid chains, each containing a targeting group - humanα MIP1 - and an antigenic group connected by the motif for dimerization. This invention also discloses a pharmaceutical composition and a vaccine against the malignancy, comprising the said dimeric protein or nucleic acid molecule and a host cell and a method for production of the said dimeric protein. Due to human MIP1 application as the targeting group toα deliver the antigen to antigen presenting cells, this invention allows to produce a vaccines inducing the antigen-specific CD8+T-cell response.EFFECT: possibility of obtaining a vaccine.92 cl, 9 dwg, 1 ex

Drugs for cancer treatment and/or prevention // 2624029
FIELD: pharmacology.SUBSTANCE: invention relates to a medicament for treatment or prevention of cancer expressing the CAPRIN-1 protein. A method for treatment or prevention of cancer expressing the CAPRIN-1 protein is also disclosed.EFFECT: invention effectively treats CAPRIN-1 mediated cancer.10 cl, 10 dwg, 1 tbl, 7 ex

Heteromultimeric proteins production // 2624027
FIELD: biotechnology.SUBSTANCE: present invention provides methods for production of heteromultimeric proteins with the ability to specifically bind to more than one target (versions), as well as methods for creation of combinatorial libraries of such heteromultimeric proteins (versions). The described methods comprise culturing of the first host cell expressing the first heavy and light chains, and the second host cell expressing the second heavy and light chains, obtaining of a combined culture containing the first and the second host cells to form a heteromultimeric protein.EFFECT: this invention allows efficient and high level genes expression and simple assembly of heteromultimeric proteins.52 cl, 49 dwg, 4 tbl, 7 ex

Polypeptides and polynucleotides and their use for treatment of immune disorders and cancer // 2623161
FIELD: biotechnology.SUBSTANCE: invention relates to isolated neutralizing antibodies specific to extracellular domains of LSR protein and can be used in medicine. Antibodies and a pharmaceutical composition with a neutralizing activity are obtained via immunization of a mammal with LSR protein with the SEQ ID NO: 11, 13, 15-17 or 18 and subsequent isolation.EFFECT: invention makes it possible to make pharmaceuticals for immunotherapy which are effective for the treatment of diseases associated with a decreased activation of T-cells mediated by LSR protein.27 cl, 38 dwg, 20 tbl, 50 ex

onoclonal antibodies and methods for their application // 2623122
FIELD: veterinary medicine.SUBSTANCE: group of inventions relates to a dedicated monoclonal antibody that binds to dog CD20. The group of inventions also relates to a method for treatment of lymphoma in a dog, comprising administrtion of at least one effective dose of the said monoclonal antibody; nucleic acid encoding the said monoclonal antibody.EFFECT: effective treatment of lymphoma in dogs.16 cl, 4 ex, 6 dwg, 7 tbl
ethod for arterial rigidity correction in patients with rheumatoid arthritis // 2623082
FIELD: medicine.SUBSTANCE: method includes introduction of Golimumab at a dose of 50 mg SC 1 times in 4 weeks on the same day to a patient with active disease and ineffectiveness of previous therapy with methotrexate and/or other synthetic DMARDs as a basic anti-inflammatory therapy.EFFECT: reduction of arterial stiffness in this category of patients due to vasoprotective action of Golimumab both on large elastic-type vessels and small muscle type arteries.1 tbl, 1 ex

Compositions and methods for malignant neoplasms prevention and treatment // 2623038
FIELD: medicine.SUBSTANCE: group of inventions relates to a method of tumour treatment, comprising administering of a nanoparticle complex, where the nanoparticle complex includes costimulatory molecules complexes and antigen/MHC complexes, where each costimulatory complex and each antigen/MHC complex is operably linked to the nanoparticle core. The group of inventions also relates to a method of distribution and/or development of antigen specific anti-tumour T-cells populations in the subject; a method for malignant tumour metastasis inhibition.EFFECT: effective operating time of T cells that specifically damage the cancer cells, sufficient for significant reduction of tumour size or malignant cells number in vivo.59 cl, 12 ex, 12, dwg, 3 tbl

Liquid composition of human growth hormone with prolonged action // 2623026
FIELD: pharmacology.SUBSTANCE: group of inventions relates to an albumin-free liquid formulation of the long-acting human growth hormone (hGH) conjugate, wherein the conjugate contains human growth hormone bound to the Fc region of immunoglobulin and has a prolonged stability in vivo compared to the native form. Liquid composition of the hGH conjugate contains a buffer with a pH of 5.0-6.0, sugar alcohol, sodium chloride and a nonionic surfactant, does not contain human serum albumin and other hazards that may be potentially contaminated with viruses.EFFECT: group of inventions provides excellent storage stability, adapted for the hGH prolonged-action conjugate, and stability in vivo compared to the native form.17 cl, 2 dwg, 11 tbl, 7 ex

Anti-notch1 antibodies // 2622083
FIELD: biotechnology.SUBSTANCE: antibodies are proposed that specifically bind to Notch1. Also, nucleic acids that encode said antibodies, vectors, host cells and methods for producing antibodies are proposed. In addition, the invention relates to a pharmaceutical composition comprising these antibodies and methods for treating disorders, mediated from Notch1, by said antibodies or a pharmaceutical composition containing them.EFFECT: invention can be used in therapy against Notch1 for the treatment of cancer.27 cl, 30 dwg, 45 tbl, 11 ex
ethod for combined treatment of macular oedema of retina // 2622031
FIELD: medicine.SUBSTANCE: method for conbined treatment of macular oedema of retina includes intravitreous introduction of bevacizumab, carrying out retina laser coagulation, as well as additional subtenon injection of diprospan. Treatment is realised in three stages: first diprospan is introduced in dose 0.5 ml, then after 10-15 days laser coagulation of retina is performed and 15-20 days after laser coagulation bevacizumab in dose 0.05 ml is introduced.EFFECT: reduction of frequency of intravotreous injections of neoangiogenesis inhibitors, stable increase of vision acuity, reduction of risk of development of side effects, associated with carrying out photodynamic therapy.2 ex

Cachexia therapy // 2622021
FIELD: medicine.SUBSTANCE: pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of Ab to IL-1α is administered to a patient. The group of inventions relates to a method for increasing longevity with cachexia.EFFECT: application of monoclonal antibodies to IL-1α has an impact on cachexia symptoms, allowing to stop the dry weight loss process and to increases life expectancy of such patients.10 cl, 1 dwg, 1 tbl, 5 ex

Antibody agains csf-1r // 2621859
FIELD: biotechnology.SUBSTANCE: proposed allocated recombinant or purified antibody that specifically binds to the receptor of colony stimulating factor-1 (CSF-1R, CSF-1R), characterized by amino acid sequences of the variable domains. Also is provided nucleic acid encoding the antibody of the invention, vector, cell and method of producing the antibody. Furthermore, a pharmaceutical composition and the use of the antibodies and pharmaceutical composition of the invention as a medicament for the treatment of cancer, disease associated with increased osteoclast activity, inflammatory disease and rheumatoid arthritis, are described.EFFECT: invention may find further application in the treatment of diseases associated with the CSF-1R.19 cl, 32 dwg, 4 tbl

ultispecific antigen-binding molecule with alternate function to blood coagulation factor viii function // 2620071
FIELD: biotechnology.SUBSTANCE: invention relates to a bispecific antibody that binds to both blood coagulation factor IX/activated blood coagulation factor IX, and blood coagulation factor X, and functionally replaces blood coagulation factor VIII. This invention discloses the nucleic acid encoding the said bispecific antibody, a vector, a cell and a method for antibody production, as well as a pharmaceutical composition and a kit for use in the method for prevention and/or treatment of bleeding or diseases associated with or caused by bleeding.EFFECT: invention may find further application for treatment of diseases associated with impaired blood clotting, such as acquired hemophilia and von Willebrand disease.17 cl, 6 dwg, 2 ex

Binding molecule specific for her3, and their applications // 2620068
FIELD: chemistry.SUBSTANCE: antibodies and antigen binding fragments thereof are described, that bind an extracellular domain of HER3 receptor and inhibit various functions associated with HER3 receptor by means of a ligand-dependent and/or ligand-independent mechanism. The compositions with increased half-life are represented as well. Furthermore, invention relates to compositions and methods for diagnosis and treatment of diseases associated with HER3-mediated signal transduction.EFFECT: invention expands the arsenal of diagnostic tools and treatment of diseases associated with HER3-mediated signal transduction.23 cl, 37 dwg, 7 tbl, 4 ex

Tetrahydrofolates in combination with egfr inhibitors // 2619335
FIELD: pharmacology.SUBSTANCE: invention is a method for colorectal adenocarcinoma treatment comprising administration of a composition comprising an effective amount of methylenetetrahydrofolate and cetuximab, wherein the method excludes application of 5-FU, its analogs, prodrugs and/or metabolites.EFFECT: potentiation of cetuximab against tumour growth in the absence of 5-FU, as well as expansion of the arsenal for colorectal adenocarcinoma treatment.6 cl, 1 ex, 2 tbl, 4 dwg

Human xcr1 antibodies // 2619180
FIELD: biotechnology.SUBSTANCE: invention refers to the field of biochemistry, in particular, to an antibody that specifically binds to human XCR1. Also the conjugate contains the specified antibody, pharmaceutical composition containing the specified antibody for the treatment of immune-associated diseases and nucleic acid coding the specified antibody are discovered. A way of treatment of immune-associated disease with the introduction of the specified antibody is discovered.EFFECT: invention allows effective treatment of immune-associated diseases.16 cl, 26 dwg, 15 tbl, 14 ex

Pcsk9 antagonists // 2618869
FIELD: medicine.SUBSTANCE: present invention relates to medicine and biotechnology. Application of aqueous composition for preparing drug for reducing blood cholesterol and/or levels of low-density lipoproteins (LDL) in blood and/or reduction of disease incidence or correcting abnormal cholesterol and/or levels of lipoproteins is proposed, caused by disturbed cholesterol metabolism and/or lipoproteins, including hypercholesteremia, dyslipidemia, atherosclerosis, hyperlipidaemia and cardiovascular disease, where said composition contains from approximately 1 mg/ml to approximately 200 mg/ml of antibody-antagonist, which specifically binds with proprotein convertase of subtilisin-kexin type 9 PCSK9; from approximately 1 mm to approximately 100 mm of histidine buffer; from approximately 0.01 mg/ml to approximately 10 mg/ml of polysorbate 80; from approximately 100 mm to nearly 400 mm of trehalose; and from 0.01 mm to approximately 1.0 mm of EDTA disodium dihydrate. Antibody in above composition effectively reduces LDL-cholesterol levels.EFFECT: in this regard present invention can find further application in therapy of diseases associated with elevated levels of cholesterol-LDL.6 cl, 24 dwg, 9 tbl, 9 ex

ethod of reducing basophils number // 2618455
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to allergology, and can be used for reduction of number of basophils in humans. For this patient gets approximately 0.03 mg/kg of monoclonal, chimeric, humanized or human antibody, which binds interleukin receptor IL-5R and includes Fc region of immunoglobulin, not containing fucose. Application of this antibody reduces number of basophils in peripheral blood in human circulatory system 24 hours after administration.EFFECT: application of given method enables to induce stable reduction of basophils by single intravenous dose of antibody.9 cl, 1 tbl, 14 ex, 31 dwg

Antibodies to human csf-1r and use thereof // 2617971
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry. Antibody against human macrophage colony-stimulating factor 1 receptor (CSF-1R) is presented. Invention also relates to method of producing above antibody, pharmaceutical composition and use of above antibody.EFFECT: invention enables inhibiting binding of CSF-1 with CSF-1R and can be used for treating cancer, bone loss, inflammatory diseases, as well as for preventing or treating metastases.12 cl, 1 dwg, 7 tbl, 8 ex

Antibodies without fc-fragment including two fab-fragment and methods of application // 2617970
FIELD: medicine, pharmacy.SUBSTANCE: group of inventions refers to biotechnology, namely to bispecific antibodies, and application thereof. The bispecific antibodies comprise two Fab fragments, the first Fab fragment comprises at least one antigen-binding site specific for the first antigen and the second Fab fragment comprises at least one antigen-binding site specific for the second antigen, where variable regions or constant regions between heavy and light chains of the second Fab fragment are exchanged, at that, the bispecific antibody lacks the Fc domain. A method and a host cell for their preparation as well as a pharmaceutical composition and an immunoconjugate for cancer treatment containing such bispecific antibodies are also proposed. The advantage of the claimed bispecific antibodies is the reduced fragments aggregation, improved stability, and improved efficiency of binding to antigen.EFFECT: invention allows effective cancer therapy.13 cl, 23 dwg, 2 tbl, 9 ex

Antibodies to human csf-1r and use thereof // 2617966
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry. Antibody against human macrophage colony-stimulating factor 1 receptor (CSF-1R) is presented. Invention also relates to method of producing above antibody, pharmaceutical composition and use of above antibody.EFFECT: invention enables inhibiting binding of CSF-1 with CSF-1R and can be used for treating cancer, bone loss, inflammatory diseases, as well as for preventing or treating metastases.12 cl, 1 dwg, 7 tbl, 8 ex

Bispecific single-chain antibody to psmaxcd3 with interspecies specificity // 2617942
FIELD: biotechnology.SUBSTANCE: bispecific single-chain antibody molecule comprising the first binding domain capable of binding to an epitope of the CD3 (Epsilon)-chain of human and common marmoset (Callithrix jacchus), oedipus tamarins (Saguinis oedipus) or common squirrel monkey (Saimiri sciureus), wherein said epitope comprises at least the amino acid sequence Gln-Asp-Gly-Asn-Glu (QDGNE) and a second binding domain capable of binding to a specific membrane antigen of human (PSMA) and cynomolgus monkey prostate, is proposed. Also are described nucleic acid encoding a bispecific single chain antibody molecule, a host cell and a method for producing the bispecific single chain antibody molecule of the invention. Also are considered a pharmaceutical composition for the prevention, treatment or amelioration of cancer associated with the expression of PSMA, and the application of the bispecific single chain antibody molecule for manufacturing of such pharmaceutical composition.EFFECT: invention may find further application in the treatment of diseases associated with the PSMA.16 cl, 2 dwg, 4 tbl, 3 ex

Preparations of antibodies // 2617532
FIELD: medicine.SUBSTANCE: present group of inventions relates to medicine. Antibody preparation is disclosed containing IgG, IgA and at least 5 % of IgM antibodies by weight of total amount of antibodies having specific activity of complement activation, wherein in in vitro analysis of antibody preparation it essentially does not form C5a and/or essentially does not form C3a. Use of antibody preparation for preparing medicinal agent for treating immunological disorders or bacterial infection and method of treating patient suffering from immunological disorder or bacterial infection are disclosed.EFFECT: presented group of inventions provides effective agents and methods of complement activation.28 cl, 3 dwg, 13 tbl, 11 ex

Selective elimination of erosion cells // 2617056
FIELD: medicine.SUBSTANCE: for treatment of the said conditions, anti-NKG2A-antibody or antigen binding fragment thereof are applied.EFFECT: use of inventions allows to stop bone erosion or cartilage destruction, mediated by osteoclasts and fibroblast-like synoviocytes, by lysis of the latter using specific NK-cells of the synovial membrane expressing NKG2A, induced by anti-NKG2A-antibodies.15 cl, 25 dwg, 8 ex

Therapeutic antibodies // 2616881
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry, namely to antibody specifically binding with second loop of human C5aR.EFFECT: invention provides effective treatment of diseases, for which anti-binding with C5aR is favorable.18 cl, 6 dwg, 10 tbl, 12 ex
ethod for treatment of primary patients with locally advanced cervical cancer // 2616531
FIELD: medicine.SUBSTANCE: method involves systemic chemotherapy in combination with administration of autologous dendritic cell vaccine, the vaccine is administered to all vertices of the rhomb of Michaelis.EFFECT: use of the invention allows effective initial cancer chemotherapy for patients with locally advanced cervical cancer of the uterus T1-3N1M0, including those having metastatic regional lymph nodes, low hematology and urinary tract disease with non-confirmed tumor invasion; patients transfer to operable condition and performance of surgery in an optimal volume.2 ex
ethod for obtaining immunoglobulin preparation for external application // 2616266
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to medicine and biotechnology and deals with method for obtaining immunoglobulin preparations, purified from admixtures with salts of metals from extracts of sediment B (Cohn III fraction). Method for obtaining immunoglobulin preparation for external application includes stage of extraction of sediment B (Cohn III fraction) with sodium chloride solution, removal of ballast admixtures and separation of target product by method of ultrafiltration in presence of complexing compounds. Removal of ballast admixtures is realised by successive treatment of extract first with merthiolate in concentration 0.1%, and then with copper sulphate in concentration 0.005-0.06% with pH value 8.0.EFFECT: increase of clinical efficiency of immunoglobulin preparation for external application due to increased content of immunoglobulins of A and M classes, preservation of specific biological activity of preparation antibodies by improvement of technology of precipitation of ballast admixtures; elimination of toxic effect on patient and personnel by elimination of application of chloroform and polyethyleneglycol in precipitation of admixtures.3 ex
Specific antibody to s100a4 or its fragment (versions), method of production thereof (versions), pharmaceutical composition containing said compounds, hybridoma cell line (versions), conjugate, composition, method of preventing and/or treating cancer, metastasis, angiogenesis and inflammatory diseases, method and kit for diagnosing cancer or disease associated with inflammation (versions), method of detecting s100a4, method of making individual therapy // 2615684
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry. Antibody to S100A4 characterized by antiangiogenic activity or its fragment in fact, preserving antiangiogenic activity of above antibody are described, wherein antibody is produced by hybridoma ECACC 10022401. Antibody contains at least area VL containing sequence SEQ ID NO: 1, and at least area VH containing sequence SEQ ID NO: 2, and identifies epitope containing sequence SEQ ID NO: 3, and it is characterized by activity profile, presented in Fig. 15. Antibody to S100A4 characterized by antiangiogenic activity or its fragment in fact preserving antiangiogenic activity of above antibody are also described, wherein antibody is produced by hybridoma selected from group comprising ECACC 11051801, ECACC 11051802 and ECACC 11051803, identifies epitope containing sequence SEQ ID NO: 24, and it is characterized by activity profile, presented in Fig. 15. Use of above antibodies in certain applications is also described.EFFECT: invention extends range of products for preventing and/or treating cancer, metastasis, angiogenesis and inflammatory diseases.36 cl, 26 dwg, 4 tbl, 16 ex

Combined therapy by afucosylated antibody for cd20 with antibody for vegf // 2615459
FIELD: medicine, pharmacy.SUBSTANCE: invention refers to biotechnology, specifically to combination therapy by afucosylated antibody for CD20 and antibody for VEGF for cancer treatment, which can be used in medicine. A afucosylated humanized B-Ly1 antibody is applied in combination with the antibody for VEGF, with a composition containing tthe said antibodies for treatment of CD20-expressing cancer, and treatment of a patient suffering from CD20-expressing cancer.EFFECT: invention can effectively inhibit the growth of CD20-expressing tumors.20 cl, 1 dwg, 2 tbl

Il-1 binding proteins // 2615173
FIELD: biotechnology.SUBSTANCE: present group of invention relates to biotechnology and immunology. Bispecifical binding protein is disclosed, which contains first polypeptide chain including two variable heavy chain domains of antibody and second polypeptide chain including two variable light chain domains of antibody (DVD-Ig). Disclosed protein binds human IL-1β and IL-1α. In addition recovered nucleic acid molecule, expression vector, host cell and method of producing binding protein under invention based on their using are disclosed. Besides pharmaceutical composition, methods of reducing activity of human IL-1 and method of treating patient from inflammatory disorder are presented.EFFECT: protein under present invention has neutralizing activity with respect to human IL-1β and IL-1α and thus it can find further application in therapy of diseases associated with IL-1.15 cl, 17 tbl, 4 ex

Stable liquid pharmaceutical preparations of fused protein tnfr: fc // 2614257
FIELD: medicine, pharmacy.SUBSTANCE: invention refers to biotechnology, namely to stable pharmaceutical compositions of fused protein TNFR: Fc. Pharmaceutical compositions and kits for their application of different physical stability TNFR:Fc are obtained by using the citrate buffer system at a concentration of 25 to 120 mM and amino acid selected from the group consisting of proline and lysine, and their pharmaceutically acceptable salts at a concentration of 15 to 100 mM as a stabilizer.EFFECT: invention allows stability of pharmaceutical compositions of etanercept for long-term storage.50 cl, 1 dwg, 17 tbl, 3 ex

Alpha-v beta-8-binding antibodies // 2614252
FIELD: pharmacy.SUBSTANCE: antibodies with high affinity for β8-subunit αvβ8 proposed. Pharmaceutical composition comprising such antibodies, and methods of their application are also described. The proposed group of inventions can be used in medicine.EFFECT: improved antibody properties.23 cl, 14 dwg, 19 ex

ethod of producing human immunoglobulin // 2614119
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry. Group of inventions is described, which involves method of producing human immunoglobulin and preparation of human immunoglobulin, obtained using said method. Method includes stage of dissolving of Cohn component I+II+III or Cohn component II+III in water for injections; deposition with caprylic acid or caprylate; first stage of anion-exchange chromatography, involving bringing pH of filtrate obtained at step (2), to 5.2, cleaning by anion-exchange chromatography and obtaining eluating solution; deposition of IgM, including control of conductivity of eluating solution obtained at step (3), up to 500–1,000 µS/cm by means of water and further bringing pH to 6.0–7.3,with subsequent settling for 1–2 hours, filtration and filtrate collection; second stage of anion-exchange chromatography, involving bringing pH of filtrate obtained at step (4) to 5.6, subsequent purification by anion-exchange chromatography and collection of eluating solution; production of human immunoglobulin by dialysis of eluating solution obtained at step (5), by ultrafiltration, obtaining pharmaceutical form and inactivation of viruses.EFFECT: invention extends range of methods for producing human immunoglobulin.9 cl, 2 dwg, 3 tbl, 2 ex

Conjugated protein-active agents and methods of their production // 2613906
FIELD: pharmacy.SUBSTANCE: conjugated protein active agent has an amino acid motif which can be recognized via isoprenoid transferase, wherein the active agent is covalently bound via at least one linker with izosubstrate, where the izosubstrat contains at least one isoprene unit and is a recognizable isoprenoid transferase, which is attached to a cysteine residue of the amino acid motif. The invention also relates to a composition comprising conjugates, and to methods for preparing conjugates and compositions.EFFECT: use of the conjugates for the delivery of the active agent into target cells with a high selectivity.16 cl, 27 dwg, 5 ex

Liquid composition of long-acting alpha interferon conjugate // 2613905
FIELD: medicine, pharmacy.SUBSTANCE: group of inventions refers to the field of pharmacy and medicine and relates to a liquid composition (options), in which the long-acting INF conjugateα and the immunoglobulin Fc-fragment are covalently linked by a non-peptidic polymer, and includes a stabilizer with a buffer, sugar alcohol, a nonionic surfactant and an isotonic agent; at that, it does not contain human serum albumin and other potential factors harmful for the organism. The inventive method for liquid composition production and a stabilizer are also stated.EFFECT: group of inventions provides excellent storage stability of long-acting INF conjugatesα with improved durability and stability in vivo, can be safely stored for a long period of time.17 cl, 1 dwg, 6 ex, 12 tbl
Production method of brucellar monospecific serum anti-melitensis // 2613901
FIELD: veterinary medicine.SUBSTANCE: provide the immunizations of rabbits with a single dose of B. melitensis strain. The rabbits immunization is carried out subdermally in the dewlap area with suspension of 1 ml volume, which contains:. 200 million MK inactivated culture of B. melitensis strain 16M with adjuvant MONTANIDE™ ISA 61 VG. At the 14th-16th day the trial blood collecting is conducted, and at the 21st-45th day the three-time blood collecting is carried out and at the 60th day it is dehematized. The serum is obtained and inactivated at 60-65°C during 1-1.5 hours. The cross adsorption with bacteriological weight of B. abortus 544 strain is carried out, obtained by culture growing within 70-72 hours. Centrifuge with cooling the residue during 24-26 hours, adding to the residue the physiological solution for obtaining the bacterial weight in the amount of 3.5-3.7×109 pfu per 10 ml of serum. Further incubate at 37°C for 2 hours and restore the serum by centrifugation with further preserving and packaging.EFFECT: utilisation of this method allows the use the inactivated Brucella culture to produce a monospecific serum, and take blood from each of the rabbits for at least four-times, increasing the amount of the resulting serum.2 ex, 8 tbl

Antibody for blys // 2613422
FIELD: medicine, pharmacy.SUBSTANCE: invention refers to biochemistry. The antibody for BLyS is stated. The invention also relates to the DNA molecule encoding the said antibody, the expression vector and the host cell to produce the said antibody. It is also proposed to use BLyS antibodies in a pharmaceutical composition and in the method for prevention and/or treatment of diseases caused by excessive proliferation of B-cells, such as systemic lupus erythematosus. The invention allows binding to BLyS with high affinity and inhibition of binding to its receptor with high BR3 specificity.EFFECT: invention adds a new BLyS antibody concept to biochemistry with a proposal to use the antibody for prevention and/or treatment of diseases caused by excessive proliferation of B-cells.15 cl, 10 dwg, 4 tbl, 10 ex

ethod for preparing composition of immunoglobulins // 2612899
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology. Disclosed is method for producing composition containing IgM immunoglobulins from plasma fractions. Also described is antibody preparation produced by such method, and use of this preparation for therapy of patients or preparing medicine for treating immunological disorders and bacterial infections.EFFECT: method involves providing plasma fraction in form of solution containing immunoglobulins, mixing solution with octanoic acid, treatment of mixed solution in vibromixer for deposition of contaminating proteins, and separation of deposited proteins from solution to obtain composition containing IgM from immunoglobulins.30 cl, 1 dwg, 11 tbl, 9 ex
 
2550888.
Up!